Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).

@article{Schernthaner2015EfficacyAT,
  title={Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).},
  author={Guntram Schernthaner and Santiago Dur{\'a}n-Garc{\'i}a and Markolf Hanefeld and Gisle Langslet and Leo Niskanen and Carl Johan {\"O}stgren and Elmas Malvolti and Elise Hardy},
  journal={Diabetes, obesity & metabolism},
  year={2015},
  volume={17 7},
  pages={630-8}
}
AIMS To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes (T2D) and inadequate glycaemic control. METHODS In this multinational, randomized, double-blind, phase IIIb/IV study (GENERATION; NCT01006603), patients aged ≥65 years were randomized (1 : 1) to receive saxagliptin 5 mg/day or glimepiride ≤6 mg/day, added to metformin, during a 52-week treatment period. The primary endpoint was achievement of glycated haemoglobin (HbA1c) <7… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Glimepiride 4 mg tablets: summary of product characteristics

  • Accord Healthcare
  • http://www.medicines.org.uk/EMC/history/25845/SPC…
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…